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ABSTRACT
Background. Tumor stroma plays an important role in the
progression and metastasis of colon cancer. The glycoproteins
versican and lumican are overexpressed in colon carcinomas
and are associated with the formation of tumor stroma. The
aim of the present study was to investigate the potential
prognostic value of versican and lumican expression in the
epithelial and stromal compartment of Union for International
Cancer Control (UICC) stage II and III colon cancer.
Methods. Clinicopathological data and tissue samples were
collected from stage II (n = 226) and stage III (n = 160)
colon cancer patients. Tissue microarrays were constructed
with cores taken from both the center and the periphery of the
tumor. These were immunohistochemically stained for lu-
mican and versican. Expression levels were scored on
digitized slides. Statistical evaluation was performed.
Results. Versican expression by epithelial cells in the
periphery of the tumor, i.e., near the invasive front, was
correlated to a longer disease-free survival for the whole
cohort (P = 0.01), stage III patients only (P = 0.01), stage
III patients with microsatellite-instable tumors (P = 0.04),
and stage III patients with microsatellite-stable tumors who
did not receive adjuvant chemotherapy (P = 0.006).
Lumican expression in epithelial cells overall in the tumor
was correlated to a longer disease-specific survival in stage
II patients (P = 0.05) and to a longer disease-free survival
and disease-specific survival in microsatellite-stable stage
II patients (P = 0.02 and P = 0.004).
Conclusions. Protein expression of versican and lumican
predicted good clinical outcome for stage III and II colon
cancer patients, respectively.
Colorectal cancer is one of the most prevalent forms of
cancer, with an annual worldwide incidence of more than 1
million cases.1 Currently, treatment and prognosis of colon
cancer patients are primarily based on the tumor, node,
metastasis staging system classification.2 This staging is
used to stratify patients for adjuvant chemotherapy. Stage III
colon cancer patients (T1–4, N1–2, M0) generally receive
adjuvant chemotherapy, whereas for stage II colon cancer
patients (T3–4, N0, M0), standard adjuvant chemotherapy is
not recommended, except for stage II patients with high-risk
features.3,4 However, 20–30 % of patients with stage II
disease will still experience relapse, and therefore, the cur-
rent system for selecting patients for adjuvant treatment
leaves room for improvement.5,6 In this respect, molecular
features reflecting tumor biology could help in optimizing
patient selection for adjuvant chemotherapy.
The tumor biology of colon cancer is heterogeneous;
different patterns of combinations of (epi)genetic and
genomic changes exist that lead to the progression from
normal colon epithelium to invasive cancer.7 One of these
molecular changes is microsatellite instability (MSI),
which occurs in 15 % of colon cancers and predicts a more
favorable outcome; it is therefore regarded as a prognostic
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factor.8 In addition, the formation of a tumor-specific
microenvironment, or tumor stroma, contributes to tumor
progression. The interplay between cancer cells and the
surrounding tumor stroma results in production of growth
signals as well as survival signals to evade apoptosis, to
facilitate migration and metastasis through remodeling of
the extracellular matrix (ECM), and to provide oxygen and
nutrients through angiogenesis.9,10 The extent to which the
surrounding stroma influences the development of colon
cancer metastasis is not fully understood. In a number of
studies, desmoplastic changes and stroma percentage were
found to be correlated with disease recurrence in stage II
patients.11,12 In addition, specific genomic alterations in
colon cancer cells that have prognostic value were found to
be associated with the percentage of tumor stroma.13–15
A genome wide mRNA expression study of colorectal
adenomas versus carcinomas revealed the stroma activation
pathway to be significantly upregulated in carcinomas.16,17
The genes that were upregulated in carcinomas encoded
several stroma-associated glycoproteins, two of which were
versican and lumican. Versican (gene symbol VCAN)
belongs to the family of large chondroitin sulfate proteo-
glycans and has hyaluronate binding properties.18,19
Lumican (gene symbol LUM) is a member of the small
leucine-rich proteoglycan family and has a role in fibrillar
network formation. Both versican and lumican play a role in
the formation of tumor-specific ECM that can support cancer
cell growth and metastasis.20,21
The aim of the present study was to investigate the
potential prognostic value of lumican and versican expres-




From 454 Union for International Cancer Control (UICC)
stage II and III colon cancer patients who underwent surgical
resection at the Kennemer Gasthuis hospital in Haarlem, the
Netherlands, as previously described, we selected a total of
386 patients to include in this study.2,22 Patients with a history
of colorectal malignancy (n = 12) and those with incomplete
resections of the primary tumor (macroscopically or micro-
scopically, n = 9) were excluded from this study. Also
patients who were lost to follow-up or who died within
3 months after surgery (n = 8 and n = 39, respectively) were
excluded. Patients with stage III colon cancer and patients
with stage II colon cancer that showed features associated with
unfavorable outcome, such as inadequately sampled nodes,
T4 lesions, perforation, or poorly differentiated histology,
were considered for adjuvant chemotherapy. Individual
patient variables like age and physical condition are of
influence on the final decision for adjuvant chemotherapy. Of
the 386 patients, 122 were treated with adjuvant chemother-
apy, which was in all cases 5-fluorouracil plus leucovorin.
Clinicopathological characteristics were collected from the
histopathology reports (Table 1). Disease recurrence was
defined as either local tumor recurrence or distant metastasis,
diagnosed by computed tomographic imaging and/or histo-
pathology. Collection, storage, and use of tissue and patient
data were performed in accordance with the Code for Proper
Secondary Use of Human Tissue in the Netherlands.23
Construction of Tissue Microarrays
Tissue microarrays were constructed using the series of
386 stage II and III colon tumors previously characterized
for MSI status.22 In brief, three 0.6-mm cores were taken
from the center of the tumor and three cores from the
periphery of the tumor and transferred to an acceptor block,
giving six cores per tumor in total (Supplementary Fig. 1).
Immunohistochemistry Protocols
Sections (4 lm thick) were deparaffinized and rehy-
drated. Endogenous peroxidases were blocked with 0.3 %
hydrogen peroxide in methanol. For the versican staining,
antigens were retrieved by microwaving for 30 min at 90 W
in 10 mM citrate buffer solution (pH 6.0). Primary mouse
anti-versican antibody (clone 2-B-1, Seikagaku, Tokyo,
Japan) was incubated at a 1:300 dilution in phosphate-buf-
fered saline containing 1 % bovine serum albumin and 0.1 %
Tween 20 (Sigma-Aldrich, St. Louis, MO, USA) at 4 C
overnight, and subsequently detected by a horseradish per-
oxidase–coupled anti-mouse polymer (Envision, Dako,
Heverlee, Belgium) followed by incubation with diam-
inobenzidine (Dako). For the lumican staining, antigens
were retrieved by autoclaving in 10 mM Tris/1 mM EDTA
buffer (pH 9.0). The primary rabbit anti-lumican antibody
(HPA001522; Atlas Antibodies, Stockholm, Sweden) was
incubated at a dilution of 1:50 in antibody diluent (Dako)
overnight at 4 C. Staining was detected by incubation with a
horseradish peroxidase–coupled anti-rabbit polymer and
incubation with diaminobenzidine (Dako). All sections were
counterstained with Mayer hematoxylin.
Evaluation of Immunohistochemistry Stainings
The stained sections were automatically scanned with a
digital pathology system (Mirax slide Scanner system
3DHISTECH, Budapest, Hungary), equipped with a 9 20
objective with a numerical aperture of 0.75 and a Sony DFW-
X710 Fire Wire 1/3-inch type progressive SCAN IT CCD
(pixel size 4.65 9 4.65 lm). The actual scan resolution
(effective pixel size in the sample plane) at 9 20 is 0.23 lm.
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All samples were examined and scored by one investigator
(EJTh.B.), and 10 % were scored independently by a second
investigator (H.B.) in a blinded fashion with a high inter-
observer agreement (Cohen’s weighted kappa value
Kw = 0.73). The scoring was performed by dedicated tissue
microarray scoring software (3DHISTECH) running on a
high-end PC with a color calibrated high-resolution com-
puter screen. To facilitate scoring, a chart with visual analog
scales of staining patterns were used. The staining in the
tumor epithelium was scored into four categories as negative,
weak, moderate, or strong. Staining in the surrounding ECM
was also scored in the same four categories. The versican
staining was very strong; therefore, to distinguish between
high- and low-expressing tumors, we used the lowest score of
multiple cores for each tumor for further analysis. For the
lumican staining, we used the highest score of multiple cores
from each tumor for further analysis.
By means of receiver operating characteristics curve
analysis, which we used to determine the optimal cutoff
score, the patients were divided into a negative and a positive
(weak, moderate, and strong combined) group for both
proteins.24 Differences in staining intensity were analyzed
separately for cores from the center of the tumor, the
periphery or overall, i.e., all cores in the tumor combined.
Staining in the epithelium and stroma was analyzed sepa-
rately, resulting in six different analyses for each staining:
colon tumor epithelium scores for the center, periphery, and
overall; and colon tumor stromal score for the center,
periphery, and overall. Because of the loss of cores during the
staining procedure (as for technical reasons), not all of the
386 patients were included in the end, leaving 328 to 371
patients per category (Supplementary Tables 1 and 2).
Statistical Methods
Pearson’s Chi-square test or Fisher’s exact test, which-
ever was appropriate, was applied to evaluate associations
between categorical variables; t-testing was applied for







Mean ± SD 71.0 ± 11.9
Median (range) 72.9 (28.5–94.0)




Mean ± SD 42.2 ± 19.5
Median (range) 40.0 (10–130)










Angioinvasive growth, n (%)
Yes 78 (20.2)
No 308 (79.8)









No. of lymph nodes examined
Mean ± SD 8.9 ± 5.2
Median (range) 8 (0–38)
Disease stage, n (%)
UICC II 226 (58.5)
UICC III 160 (41.5)









Yes, local 23 (6)
Yes, distant 20 (5.2)
Yes both local and distant 84 (21.8)
No 259 (67.1)
Follow-up (mo)
Mean ± SD 60.4 ± 33.7
Median (range) 57.2 (2.8–148.6)
a Chemotherapy in all cases was 5-fluorouracil plus leucovorin
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investigation of associations between the staining categories
and means of, e.g., tumor size. Survival rates were displayed
as Kaplan–Meier curves and compared by the log-rank test.
All statistical tests were two sided, and P values of B 0.05
were considered significant. Multivariate analyses were
performed by the forward conditional method (P-value for
variables to remain in the model was P B 0.05). Input
variables were all first tested individually for correlation to
disease recurrence, and significant terms were included in the
multivariate model (Table 2). All statistical analysis was
performed by SPSS Statistics software, version 15.0 (SPSS,
Chicago, IL, USA).
RESULTS
Versican and Lumican Protein Expression
and Clinicopathological Characteristics
Both versican and lumican were expressed in the stromal as
well as in the epithelial tumor compartment (Fig. 1). Versican
staining in the epithelial cells was usually cytoplasmic with
sometimes intensely stained granular areas within the cyto-
plasm, most likely the Golgi system. Staining in the epithelial
cells was usually accompanied with staining in the stroma,
with endothelial- and myofibroblast-like cells showing posi-
tivity for versican. Lumican staining in the epithelium was
also mostly cytoplasmic, often combined with a clear apical
membrane staining, while stromal staining usually was dif-
fuse. In epithelial cells, versican staining was observed in 231
tumors (62.3 %) while epithelial lumican staining was
observed in 243 tumors (66.2 %). Stromal versican staining
was seen in 304 tumors (81.9 %), and stromal lumican
staining was present in 336 tumors (91.6 %).
Versican staining in epithelial cells was associated with
several clinicopathological factors, including tumor size
(P = 0.002), mucinous differentiation (P = 0.001), and
histological grade (P = 0.01) (Supplementary Table 1).
Stromal versican expression was more often present in the
central area of the tumor in stage III patients than in stage
II patients (P = 0.04), and mucinous tumors had less
versican expression in the stroma of the periphery of the
tumor (P = 0.002). Lumican expression was also corre-
lated to several tumor characteristics (Supplementary
Table 2). Tumors with lumican expression overall in the
epithelial cells were smaller than lumican-negative tumors
(P = 0.04). Stromal lumican expression overall was less
frequently observed in mucinous tumors (P = 0.005).
Versican Expression in the Tumor Periphery Predicts
Good Outcome in Stage III Patients
Lack of versican expression in the epithelial cells in the
tumor periphery was significantly associated with recurrent
disease (P = 0.01, Supplementary Table 1). Survival
analysis for versican expression in the tumor periphery
revealed that in the whole study population, versican
expression correlated to a longer disease-free survival
(DFS), as well as a longer disease-specific survival (DSS),
(P = 0.01 and P = 0.02, respectively; Fig. 2a,b). When
stage II and stage III patients were analyzed separately,
versican expression was correlated to a longer DFS and
DSS for stage III patients (P = 0.01 and P = 0.002,
respectively; Fig. 2e,f), while no significant association
was found for stage II (Fig. 2c,d).
The presence of MSI is generally considered to indicate
a more favorable prognosis; therefore, the prognostic effect
of versican was examined in the stage III microsatellite-
TABLE 2 Multivariate analysis of disease recurrence
Variable Wald Odds ratio 95 % confidence interval P
Recurrence in stage II and III patientsa
N stage (1) 8.9 0.3 0.1–0.7 0.003
Angioinvasive growth 5.6 0.5 0.2–0.9 0.02
Versican expression in periphery of the tumor 3.8 1.9 1.0–3.5 0.05
Recurrence in stage III patients (versican)b
Angioinvasive growth 9.8 0.3 0.1–0.6 0.002
Versican expression in periphery of the tumor 4.3 2.5 1.1–5.8 0.04
Recurrence in stage II MSS patients (lumican)c
Lumican expression in the cytoplasm 4.6 2.4 1.1–5.1 0.03
a Input: adjuvant chemotherapy, angioinvasive growth, MSI, lumican expression in the epithelial cells of the tumor, versican expression in the
periphery of the tumor, differentiation grade, T stage, N stage, and stage
b Input: adjuvant chemotherapy, MSI status, angioinvasive growth, versican expression in periphery of the tumor, differentiation grade, T stage,
N stage
c Input: adjuvant chemotherapy, angioinvasive growth, lumican expression the epithelial cells of the tumor, differentiation grade, T stage
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stable (MSS) (n = 106) and stage III MSI (n = 24) patient
subgroups. The MSI status in this patient cohort was
determined previously.22 MSI tumors more frequently
lacked epithelial versican expression overall (P = 0.005)
as well as in the center (P = 0.01) and the periphery
(P = 0.001) of the tumor. This observation is in line with
the finding that mucinous tumors, a phenotype associated
with MSI, had also less versican expression in the epithelial
cells in both areas of the tumor. Because there was a sig-
nificant correlation of versican expression in the epithelial
cells in the periphery to several possible prognostic factors
such as MSI status and lymphovascular invasion, survival
analysis was performed on several subgroups. For the rel-
atively small subgroup of 24 stage III MSI tumors, patients
with tumors that were positive for versican staining in the
periphery had a significantly better survival time than the
versican-negative group (DFS P = 0.04, DSS P = 0.02;
Fig. 3a,b). For stage III MSS patients, there was no sig-
nificant difference in survival between those with and
without versican-expressing tumors (Fig. 3c,d).
Most of the stage III patients received adjuvant chemo-
therapy, which is expected to influence disease outcome.
Therefore, the prognostic effect of versican was reevaluated
in the stage III MSS patient group that received adjuvant
chemotherapy (n = 62) or those patients who did not receive
adjuvant chemotherapy (n = 44). For patients who did not
receive adjuvant chemotherapy, the versican-negative sub-
group (n = 6) had a significantly shorter survival time (DFS
P = 0.006, DSS P = 0.001) than the versican-positive
group (n = 38) (Fig. 3e,f). These differences were not
observed in patients who received chemotherapy (Fig. 3e,f).
The subgroup of stage III patients with MSI tumors who did
not receive adjuvant chemotherapy contained too few cases
to permit meaningful analysis.
Lumican Expression in the Epithelial Cells Predicts
Good Outcome for Stage II MSS Patients
For the stage II and III patients combined, lumican
expression did not correlate with disease recurrence
(Fig. 4a,b). However, stage II patients positive for lumican
expression in the epithelial cells overall in the tumor did
show a trend toward longer DSS (DFS P = 0.2, DSS
P = 0.05; Fig. 4c,d). This effect was not observed in stage
III patients (Fig. 4e,f).
The potential prognostic effect of lumican expression for
stage II patients was further examined in the stage II MSS
(n = 140) and stage II MSI (n = 36) subgroups. Lumican
expression was more often observed in MSS tumors than in
MSI tumors in the epithelial cells in the periphery of the
tumor (P = 0.04; Supplementary Table 2). Stromal lumican
expression overall in the tumor was also more present in
FIG. 1 Expression pattern of versican and lumican proteins in colon
tumor epithelium and tumor stroma. Immunohistochemical staining
patterns ranged from weak to strong epithelial and stromal staining
for both versican and lumican. Representative examples of versican
(a–c) and lumican (d–f) staining in colon tumor epithelium and
stroma are shown. These examples were classified as negative (0),
weak (1), moderate (2), and strong (3), with expression for epithelium
(E) and stroma (S) indicated between brackets [E,S] as follows;
a [1,1], b [2,3], c [3,1], d [0,1], e [2,1], f [3,2]. Scale bar = 50 lm
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MSS tumors and less frequently observed in mucinous
tumors (both P = 0.005; Supplementary Table 2). For stage
II patients with MSI tumors, lumican expression was not
correlated with survival (Fig. 5a,b), while in patients with
stage II MSS tumors, lumican expression was indicative of
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FIG. 2 DFS and DSS of colon
cancer patients stratified by
versican expression in the
epithelial cells of the tumor
periphery. Kaplan–Meier graphs
display patients with versican-
positive (blue line) or versican-
negative (yellow line) colon
cancers. Displayed are DFS (a,
c, e) and DSS (b, d, f) for stage
II and III patients combined (a,
b), for stage II patients (c, d),
and for stage III patients (e, f)





























































I vs. IV: P = 0.006
II vs. III: P = 0.7
I vs. IV: P = 0.001
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I (n = 38)
II (n = 45)
III (n = 17)
IV (n = 6)
I (n = 38)
II (n = 45)
III (n = 17)
IV (n = 6)
FIG. 3 DFS and DSS stratified
by versican expression and MSI
status in stage III patients. a–d
Kaplan–Meier graphs for
subgroups of patients with
versican-positive (blue line) or
versican-negative (yellow line)
colon cancers. Displayed are
DFS (a, c) and DSS (b, d) for
stage III MSI patients (a, c), and
for stage III MSS patients (b, d).
e, f Stage III MSS patients
subdivided according to
adjuvant chemotherapy status
and versican expression: I
versican positive without
adjuvant chemotherapy, II
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FIG. 4 DFS and DSS stratified





(blue line) or lumican-negative
(yellow line) colon cancers.
Shown are DFS (a, c, e) and
DSS (b, d, f) for stage II and III
patients combined (a, b), for
stage II patients (c, d), and for
stage III patients (e, f)
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Multivariate Analysis: Lack of Versican and Lumican
Are Independent Risk Factors for Disease Recurrence
Multivariate logistic regression was performed to
correct for dependency between independent predictors
of outcome and to investigate whether lack of versican
and lumican expression in the tumor were independent
risk factors for disease recurrence. In the multivariate
analysis, several prognostic factors, i.e., adjuvant che-
motherapy treatment, MSI status, angioinvasive growth,
differentiation grade, T stage, and N stage, were included
(Table 2). Lack of versican expression, in addition to
presence of angioinvasive growth, and N stage were
independent risk factors of disease recurrence in the
whole study population and in stage III patients only
(P = 0.05, P = 0.04). Lack of lumican expression was
an independent prognostic factor for stage II MSS
patients (P = 0.03) (Table 2).
DISCUSSION
To our knowledge, this study is one of the first to
describe lumican and versican expression in a large cohort
of colon cancer patients in which expression in both the
epithelial compartment and the stromal compartment of the
tumor was examined. In the present study, versican
expression in the epithelial cells in the periphery of the
tumor was associated with a longer survival (Figs. 2 and 3),
whereas versican in the tumor stroma was not associated
with survival (data not shown). In addition, lack of versican
expression may predict which stage III patients would
benefit from adjuvant chemotherapy. Stage III MSS
patients without adjuvant chemotherapy that lacked versi-
can expression had a significantly worse survival than those
with versican expression in the periphery of the tumor,
while this difference was not observed among stage III
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FIG. 5 DFS and DSS stratified
by lumican expression and MSI
status in stage II patients.
Kaplan–Meier graphs display
patients with lumican-positive
(blue line) or lumican-negative
(yellow line) colon cancers.
Shown are DFS (a, c) and DSS
(b, d) for stage II MSI patients
(a, b) and for stage II MSS
patients (c, d)
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Versican is thought to stimulate cell proliferation, inhi-
bit apoptosis, and support metastasis of the tumor.25–27 In
addition, versican is associated with the formation of a
pericellular sheath that can modulate cell attachment and
motility.28 Versican is expressed and secreted by fibro-
blasts present in the tumor stroma in response to
stimulation by epithelial tumor cells, most likely regulated
via transforming growth factor beta (TGFB) and platelet-
derived growth factor (PDGF).29 Stromal versican
expression has been proposed as a prognostic biomarker for
worse disease outcome in several cancer types, including
serous ovarian cancer, oral squamous cell carcinoma, and
breast cancer.30–33 Besides the expression in the tumor
stroma, epithelial versican expression has also been
described for endometrial, cervical, and ovarian can-
cer.30,34,35 One of these studies reported the opposite
effects: versican expression in epithelial cells was corre-
lated to a longer survival, while versican expression in the
tumor stroma was indicative of shorter survival.30
Lumican staining in the epithelial cells of the tumor
overall was associated with a better outcome for stage II
colon cancer patients (Fig. 4d). When this patient group
was stratified for MSI status, we found that MSS stage II
patients with lumican expression survived longer than
those who lacked lumican expression (Fig. 5c,d). Lumican
interacts with and is regulated by several signaling path-
ways that can influence tumor progression. In ovarian
cancer, it has been shown that the oncogene HMGA2
directly binds to the promoter region of LUM leading to
downregulation of LUM expression.18 Lumican can inhibit
the activation of the focal adhesion kinase (FAK), resulting
in less cell migration.36 Also, transformation induced by
v-src and v-K-ras can be suppressed by lumican, and
enhanced expression of lumican can inhibit growth and
formation of metastasis by melanoma cells.20,30,37 Lumican
expression in tumor stroma and tumor epithelial cells has
been linked to both worse and better disease outcome in
several cancers. For advanced colorectal cancer, high lu-
mican expression in the tumor stroma has been found to
correlate with worse survival.38 In the present study,
however, we did not find a prognostic effect of lumican
expression in the tumor stroma, and the prognostic value of
staining in the tumor cells was restricted to stage II MSS
tumors. This apparent contradiction with the previous data
may be explained by a different composition of the study
population (e.g., UICC stage) and larger sample size in the
present study, as well as the fact that in the current study, in
contrast to the study of Seya et al., tumors also were
stratified for MSI.38 In breast cancer, high lumican mRNA
expression was correlated with prognostic factors indicat-
ing a worse disease outcome.39 However, low levels of
lumican protein were associated with a shorter time to
progression and a worse survival.40
Rather than continuing to consider colon cancer as a
homogenous disease, the challenge ahead is finding ways
to deal with the different molecular categories of colon
cancer, where differences in underlying tumor biology
determine clinical outcome. Inherently this approach
results in smaller subgroups of colon cancer patients to be
considered. However, the findings presented here empha-
size the relevance of molecular characterization of colon
tumors for MSI status as a factor that may influence
prognosis, in particular when studying novel markers with
potential prognostic value. Both versican and lumican
staining were more often observed in the MSS tumors, and
the prognostic value of lumican appeared to be restricted to
MSS tumors. Lumican has been proposed to have a tumor
suppressor function by preventing the activation of the
TGFB2/Smad2 signaling pathway, which results in less
cell adhesion and loss of inhibition of cell prolifera-
tion.36,41,42 One of the most frequently mutated genes in
MSI tumors is TGFBR2, which encodes a receptor of
TGFB2.43 Possibly the effects of lumican on the TGFB2/
Smad2 pathway are redundant in tumors with a mutation in
TGFBR2, which could explain the lack of prognostic value
of lumican expression for patients with MSI tumors.
Versican has also been linked to TGFB2. For example,
in gliomas, the expression of versican was upregulated via
TGFB2, and increased migration in response to exogenous
TGFB2 was observed.44 Besides TGFB2 signaling,
numerous other pathways and molecules influence versican
mRNA expression, including p53, PDGF, interleukin 1b,
and activated b-catenin.45–48 Transcriptional repressors
include the microRNA miR-199a*, which is considered to
be an oncosuppresor.49 The interplay of all of these factors
results in the regulation of versican expression, and MSI
tumors are likely to have different molecular alterations in
these pathways than MSS tumors.
The patient cohort of the presented study is one of the
few that has been stratified for MSI status while investi-
gating prognostic biomarkers in colon cancer, and the
results of this study underline the importance of that
stratification because different effects in the patient groups
with MSI or MSS tumors were observed. A possible lim-
itation of the present study is that the lymph node yield in
this retrospective cohort, i.e., 8.9 on average, is lower than
UICC recommendations (at least 12 lymph nodes) as well
as lower than the current standards in the Netherlands (at
least 10 lymph nodes); therefore, the staging of these
tumors might be suboptimal. The results presented here
emphasize that both versican and lumican are associated
with colon cancer prognosis. In combination with MSI
status, versican and lumican are putative prognostic bio-
markers that predict good outcome in stage II and III colon
cancer patients, and in the latter also with respect to the
effect of adjuvant chemotherapy.
Versican and Lumican Predict Colon Cancer Outcome S357
ACKNOWLEDGMENT Supported in part by Philips Healthcare
(Md.W.). This study was performed within the framework of CTMM,
the Center for Translational Molecular Medicine, DeCoDe project
(grant 03O-101).
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
REFERENCES
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,
2002. CA Cancer J Clin. 2005;55:74–108.
2. Hermanek P, Sobin LH. International Union Against Cancer
(UICC): TNM classification of malignant tumours. 4th ed. Hei-
delberg: Springer; 1987.
3. Van CE, Oliveira J. Primary colon cancer: ESMO clinical rec-
ommendations for diagnosis, adjuvant treatment and follow-up.
Ann Oncol. 2009;20(Suppl 4):49–50.
4. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluoro-
uracil-based adjuvant therapy for stage II and III colon cancer: who
benefits and by how much? J Clin Oncol. 2004;22:1797–806.
5. IMPACT B2 Investigators. Efficacy of adjuvant fluorouracil and
folinic acid in B2 colon cancer. International Multicentre Pooled
Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.
J Clin Oncol. 1999;17:1356–63.
6. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy
of adjuvant chemotherapy in patients with Dukes’ B versus
Dukes’ C colon cancer: results from four National Surgical
Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02,
C-03, and C-04). J Clin Oncol. 1999;17:1349–55.
7. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal
cancer. Cell. 1996;87:159–70.
8. Boland CR, Goel A. Microsatellite instability in colorectal can-
cer. Gastroenterology. 2010;138:2073–87.
9. Pietras K, Ostman A. Hallmarks of cancer: interactions with the
tumor stroma. Exp Cell Res. 2010;316:1324–31.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next gen-
eration. Cell. 2011;144:646–74.
11. Crispino P, De TG, Ciardi A, et al. Role of desmoplasia in
recurrence of stage II colorectal cancer within five years after
surgery and therapeutic implication. Cancer Invest. 2008;26:
419–25.
12. Mesker WE, Junggeburt JM, Szuhai K, et al. The carcinoma–
stromal ratio of colon carcinoma is an independent factor for
survival compared to lymph node status and tumor stage. Cell
Oncol. 2007;29:387–98.
13. Fijneman RJ, Carvalho B, Postma C, Mongera S, van Hinsbergh
VW, Meijer GA. Loss of 1p36, gain of 8q24, and loss of 9q34 are
associated with stroma percentage of colorectal cancer. Cancer
Lett. 2007;258:223–9.
14. Ogunbiyi OA, Goodfellow PJ, Gagliardi G, et al. Prognostic
value of chromosome 1p allelic loss in colon cancer. Gastroen-
terology. 1997;113:761–6.
15. Kim MY, Yim SH, Kwon MS, et al. Recurrent genomic altera-
tions with impact on survival in colorectal cancer identified by
genome-wide array comparative genomic hybridization. Gastro-
enterology. 2006;131:1913–24.
16. Sillars-Hardebol AH, Carvalho B, de Wit M, et al. Identification of
key genes for carcinogenic pathways associated with colorectal
adenoma-to-carcinoma progression. Tumour Biol. 2010;31:
89–96.
17. Carvalho B, Postma C, Mongera S, et al. Multiple putative
oncogenes at the chromosome 20q amplicon contribute to colo-
rectal adenoma to carcinoma progression. Gut. 2009;58:79–89.
18. Wu J, Liu Z, Shao C, et al. HMGA2 overexpression-induced
ovarian surface epithelial transformation is mediated through
regulation of EMT genes. Cancer Res. 2011;71:349–59.
19. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronate bind-
ing properties of versican. J Biol Chem. 1992;267:10003–10.
20. Ishiwata T, Cho K, Kawahara K, et al. Role of lumican in cancer
cells and adjacent stromal tissues in human pancreatic cancer.
Oncol Rep. 2007;18:537–43.
21. Theocharis AD. Human colon adenocarcinoma is associated with
specific post-translational modifications of versican and decorin.
Biochim Biophys Acta. 2002;20;1588:165–72.
22. Belt EJ, Fijneman RJ, van den Berg EG, et al. Loss of lamin A/C
expression in stage II and III colon cancer is associated with
disease recurrence. Eur J Cancer. 2011;47:1837–45.
23. Dutch Federation of Biomedical Scientific Societies. Code for
proper secondary use of human tissue in the Netherlands.
http://www.federa.org/.
24. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting
immunohistochemical cut-off scores for novel biomarkers of
progression and survival in colorectal cancer. J Clin Pathol.
2007;60:1112–6.
25. Sheng W, Wang G, Wang Y, et al. The roles of versican V1 and
V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell.
2005;16:1330–40.
26. Ween MP, Oehler MK, Ricciardelli C. Role of versican, hyalu-
ronan and CD44 in ovarian cancer metastasis. Int J Mol Sci.
2011;12:1009–29.
27. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of
versican with its binding partners. Cell Res. 2005;15:483–94.
28. Ricciardelli C, Russell DL, Ween MP, et al. Formation of hya-
luronan- and versican-rich pericellular matrix by prostate cancer
cells promotes cell motility. J Biol Chem. 2007;282:10814–25.
29. Mukaratirwa S, Koninkx JF, Gruys E, Nederbragt H. Mutual
paracrine effects of colorectal tumour cells and stromal cells:
modulation of tumour and stromal cell differentiation and
extracellular matrix component production in culture. Int J Exp
Pathol. 2005;86:219–29.
30. Voutilainen K, Anttila M, Sillanpaa S, et al. Versican in epithelial
ovarian cancer: relation to hyaluronan, clinicopathologic factors
and prognosis. Int J Cancer. 2003;107:359–64.
31. Ricciardelli C, Brooks JH, Suwiwat S, et al. Regulation of stro-
mal versican expression by breast cancer cells and importance to
relapse-free survival in patients with node-negative primary
breast cancer. Clin Cancer Res. 2002;8:1054–60.
32. Pukkila M, Kosunen A, Ropponen K, et al. High stromal versican
expression predicts unfavourable outcome in oral squamous cell
carcinoma. J Clin Pathol. 2007;60:267–72.
33. Ghosh S, Albitar L, Lebaron R, et al. Up-regulation of stromal
versican expression in advanced stage serous ovarian cancer.
Gynecol Oncol. 2010;119:114–20.
34. Kodama J, Hasengaowa, Kusumoto T, et al. Prognostic signifi-
cance of stromal versican expression in human endometrial
cancer. Ann Oncol. 2007;18:269–74.
35. Kodama J, Hasengaowa, Kusumoto T, et al. Versican expression
in human cervical cancer. Eur J Cancer. 2007;43:1460–6.
36. Brezillon S, Radwanska A, Zeltz C, et al. Lumican core protein
inhibits melanoma cell migration via alterations of focal adhesion
complexes. Cancer Lett. 2009;283:92–100.
37. Yoshioka N, Inoue H, Nakanishi K, et al. Isolation of transforma-
tion suppressor genes by cDNA subtraction: lumican suppresses
transformation induced by v-src and v-K-ras. J Virol. 2000;74:
1008–13.
S358 M. de Wit et al.
38. Seya T, Tanaka N, Shinji S, et al. Lumican expression in
advanced colorectal cancer with nodal metastasis correlates with
poor prognosis. Oncol Rep. 2006;16:1225–30.
39. Leygue E, Snell L, Dotzlaw H, et al. Expression of lumican in
human breast carcinoma. Cancer Res. 1998;58:1348–52.
40. Troup S, Njue C, Kliewer EV, et al. Reduced expression of the
small leucine-rich proteoglycans, lumican, and decorin is asso-
ciated with poor outcome in node-negative invasive breast
cancer. Clin Cancer Res. 2003;9:207–14.
41. Naito Z, Ishiwata T, Kurban G, et al. Expression and accumu-
lation of lumican protein in uterine cervical cancer cells at the
periphery of cancer nests. Int J Oncol. 2002;20:943–8.
42. Nikitovic D, Chalkiadaki G, Berdiaki A, et al. Lumican regulates
osteosarcoma cell adhesion by modulating TGFbeta2 activity. Int
J Biochem Cell Biol. 2011;43:928–35.
43. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II
TGF-beta receptor in colon cancer cells with microsatellite
instability. Science. 1995;268(5215):1336–8.
44. Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bog-
dahn U, Hau P. The role of versican isoforms V0/V1 in glioma
migration mediated by transforming growth factor-beta2. Br J
Cancer. 2007;96:1560–8.
45. Kamitani S, Yamauchi Y, Kawasaki S, et al. Simultaneous
stimulation with TGF-beta1 and TNF-alpha induces epithelial
mesenchymal transition in bronchial epithelial cells. Int Arch
Allergy Immunol. 2010;155:119–28.
46. Rahmani M, Wong BW, Ang L, et al. Versican: signaling to
transcriptional control pathways. Can J Physiol Pharmacol.
2006;84:77–92.
47. Theocharis AD. Versican in health and disease. Connect Tissue
Res. 2008;49:230–4.
48. Yoon H, Liyanarachchi S, Wright FA, et al. Gene expression
profiling of isogenic cells with different TP53 gene dosage
reveals numerous genes that are affected by TP53 dosage and
identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci
USA. 2002;99:15632–7.
49. Lee DY, Shatseva T, Jeyapalan Z, Du WW, Deng Z, Yang BB. A
30-untranslated region (30UTR) induces organ adhesion by regu-
lating miR-199a* functions. PLoS One. 2009;4:e4527.
Versican and Lumican Predict Colon Cancer Outcome S359
